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Abstract:  Two purified proteins G-6 and G-4-2 were obtained from Arca subcrenata 
Lischke using the homogenization, salting-out with ammonium sulfate, ion-exchange 
chromatography and gel filtration chromatography techniques. The purity of G-6 and 
G-4-2 was over 96%, as measured by RP-HPLC. G-6 and G-4-2 were measured by 
SDS-PAGE and IEF-PAGE to have molecular weights of 8.2 kDa and 16.0 kDa, and 
isoelectric points of 6.6 and 6.1, respectively. The amino acid constituents of G-6 and 
G-4-2 were also determined. The existence of saccharides in G-6 was demonstrated by the 
phenol-sulfuric acid method. G-6 and G-4-2 inhibited the proliferation of human tumor 
cells in vitro. By MTT assay, the IC50 values of G-4-2 were 22.9 µg/mL, 46.1 µg/mL and 
57.7 µg/mL against Hela, HL-60 and KB cell lines, respectively, and the IC50 value of G-6 
against HL-60 cell line was measured to be 123.2 µg/mL. 
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1. Introduction 
 
In recent years, more and more researchers have come to the realization that marine organisms hold 
immense potential as a source of novel molecules and new anticancer agents. Because of their longer 
evolutionary history, marine organisms likely possess a greater molecular diversity than do their Mar. Drugs 2008, 6  419
 
 
terrestrial counterparts [1-2]. Over the past two decades, a global collaborative effort has been raised 
that aims at the discovery of novel and clinically useful anti-tumor agents derived from marine 
organisms [3-7]. According to existing literature, more than ten new experimental anti-tumor agents 
derived from marine sources have entered clinical trials [8], including bryostatin-1, aplidine, 
ecteinascidin-743 (ET-743) [2], Kahalalide F [9], as well as derivatives of dolastatin such as TZT-1027 
[10] and LU 103793 [11]. 
Arca subcrenata Lischke is a marine invertebrate that belongs to Arcidae family under Phylum 
Mollusca, Class Lamellibranchiata. A Chinese Traditional Material, wa leng zi (Concha Arcae), is 
made from A. subcrenata. As a marine mollusk native to the seas around China, A. subcrenata has 
been utilized in the treatments of tumor, anemia and inflammation for centuries in Chinese Traditional 
medicine [12]. The concentration of protein and saccharide, proportions of amino acid, ultraviolet 
spectrum analysis and trace element analysis of A. subcrenata have been previously reported [13]. Its 
hydrolysate was found to possess hypoglycemic activity on mice with alloxan-induced hyperglycemia, 
hypolipidic activity in experimental mouse model of hyperlipidemia [14], as well as protective effects 
on liver injuries in mice [15]. More recently, polysaccharide from A. subcrenata was demonstrated to 
induce proliferation of spleen lymphocyte in vitro [16]. However, no information is currently available 
on its anti-tumor activity either in vitro or in vivo. During the course of our extensive screening 
program on marine traditional Chinese medicines for in vitro anti-tumor activities, A. subcrenata was 
selected because of its widespread geographic distribution in China and its unique reputation in 
folklore medicine.   
In our present study, purification and characterization of protein components of A. subcrenata were 
investigated. Their in vitro anti-tumor activity was also evaluated by examining cytotoxicity against 
seven human tumor cell lines. 
2. Materials and Methods 
2.1 Materials 
DEAE Sepharose Fast Flow and Sephadex G-50 were obtained from Pharmacia Biotechnology. 
L-glutamide and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased 
from Amresco Inc., Solon, Ohio, USA. Coomassie Brilliant Blue G-250 and Bovine Serum Albumin 
were obtained from Sino-American Biotechnology Co., USA. RPMI-1640 medium was purchased 
from GIBCO, USA and Cisplatin (cis-diamminedichloroplatinum, CDDP) from David Bull Laboratory. 
Fetal bovine serum (FBS) was provided by Hangzhou Sijiqing Corp, P.R. China. Benzylpenicillin 
sodium was obtained from Jiangxi Dongfeng Pharmaceutical Co., Ltd., P.R. China. Streptomycin 
sulfate was produced by North China Pharmaceutical Group Corporation. Molecular weight markers 
were obtained from Shanghai Puyi Biotechnology Co., Ltd., P.R. China. All other chemicals and 
reagents used were of analytical grade. 
2.2 Extraction of total proteins 
The visceral mass of A. subcrenata (200 g) was washed with 4 °C tap water three times, followed 
by washing with 4 °C distilled water three times. It was then homogenized with double volume of PBS Mar. Drugs 2008, 6  420
 
 
(10 mM, pH 8.0) at 4 °C for 3 min. After centrifugation (16,000 g, 20 min) at 4 °C, the supernatant 
was collected and the crude extract obtained. The crude extract of A. subcrenata was fractionated by 
salting out with increasing concentrations of ammonium sulfate. Solid ammonium sulfate was slowly 
added to the above crude extract with gentle stirring, up to 35% saturation in 20 min. After the crude 
extract was left at 4 °C with the ammonium sulfate under vortexing for another 40 min [17], the 
protein precipitate was collected by centrifugation (16,000 g, 20 min) at 4°C. The supernatant was 
transferred to another beaker, and solid ammonium sulfate was added to it up to 70% saturation. The 
mixture was treated as above. Likewise, another protein precipitate was obtained at 70%−100% 
saturation of ammonium sulfate. Each of the three protein pellets was suspended in 10 ml of ice-cold 
PBS (10 mM, pH 8.0), and dialyzed against a large volume (3 L) of distilled water for 24 h at 4 °C. 
Dialysis bags, with molecular weight cut-off (MWCO) of 1000 Da (Spectro/Pro 6: 
Spectrum-Laboratories, Inc.), were employed. During this process, the dialysate was changed three 
times to completely remove any residual ammonium sulfate. 
2.3 Purification of proteins 
Anion exchange chromatography (DEAE Sepharose Fast Flow): Fraction III obtained from the crude 
extract at 70%−100% saturation of ammonium sulfate was dialyzed against 10 mM Tris-HCl, pH 7.46 
for 5 h and the dialyzed solution was subsequently injected into a DEAE Sepharose Fast Flow column, 
which was pre-equilibrated with the aforementioned Tris-HCl buffer. The column was washed with the 
same buffer until the baseline returned to zero and remained stable. The column was then eluted with 
increasing concentration of NaCl prepared in 10 mM Tris-HCl buffer, pH 7.46 at 4 °C. Aliquots of 5 
ml/tube were collected at a flow rate of 1.2 ml/min and the absorbance was measured at 280 nm. Seven 
A280 nm peak fractions, named G-1, G-2, G-3, G-4, G-5, G-6 and G-7, were collected respectively.   
 
Gel filtration chromatography (Sephadex G-50): The protein solution that passed through the anion 
exchange chromatographic column was concentrated by freeze-drying and loaded onto a Sephadex 
G-50 column that was pre-equilibrated with 10 mM Tris-HCl buffer, pH 7.46. The flow rate was 0.65 
ml/min, and the absorbance was monitored at 280 nm. Three A280 nm peak fractions, termed as G-4-1, 
G-4-2 and G-4-3, were obtained respectively.   
2.4 Cytotoxicity assay 
Cell lines and culture: Tumor cell lines used in this study included seven human cell lines, namely 
A549 (lung cancer cells), BEL-7404 (hepatocellular carcinoma cells), CNE (nasopharyngeal 
carcinoma cells), Hela (cervical carcinoma cells), PC-3 (prostatic carcinoma cells), HL-60 (leukemia 
cells) and KB (oral epithelial cancer cells). All of cell lines were provided by Shanghai Institutes for 
Biological Sciences, Chinese Academy of Sciences, and the cells were cultured in RPMI 1640 medium 
supplemented with heat-inactivated 10% FBS, 0.2 mg/L L-glutamide, 1.0 mg/mL
 NaHCO3, 100 
units/mL penicillin, and 100 units/mL streptomycin in a humidified incubator at 37 °C and 5% CO2 
atmosphere. 
 
Evaluation of cytotoxicity: Cultured cells were taken during their exponential growth phase. Routinely, Mar. Drugs 2008, 6  421
 
 
the cells were detached with 0.25% trypsin and cell suspension was made in the above medium. By 
trypan blue exclusion, cell viability greater than 95% was determined. One hundred microliters of cell 
suspensions containing 5 × 10
3 cells were seeded in each well of a 96-well microtiter plate and 
incubated at 37 °C in a humidified incubator with 5% CO2. After 24 h, the cells were treated with 
aseptic samples which were sterilized by passing through 0.22 µm Millipore filter, and CDDP was 
used as the positive control. Untreated cells were used as negative control. Each plate was incubated 
for another 72 h at 37 °C in a humidified incubator with 5% CO2. Cytotoxic activity was evaluated in 
vitro by MTT assay [18] and is expressed as IC50, i.e. the sample concentration able to inhibit cell 
growth by 50% compared with the untreated control. All experiments were carried out in triplicate, and 
data in the form of mean ± SD are presented. 
2.5 Protein assay 
The protein content of total protein extract, fraction-I, fraction-II, fraction-III, G-6, G-4 and G-4-2 
was determined by the method of Bradford [19] with bovine serum albumin as standard. 
2.6 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
The Sodium dodecyl sulfate-polyacrylamide gel electrophoriesis  (SDS-PAGE)  analysis was 
performed with a mini-gel apparatus (Protean II. BioRAD, USA). There were two SDS- PAGE 
systems employed. The samples were analyzed by SDS-PAGE in Laemmli gel [20] with an acrylamide 
concentration of 5% for the stacking gel and 12% for the running gel, as well as in Tricine-SDS-PAGE 
[21] with an acrylamide concentration of 4% for the stacking gel, 10% for the space gel and 15.5% for 
the running gel. Five to thirty micrograms of protein per well was loaded on the gel. Protein bands 
were detected by the Coomassie blue staining method [22]. 
2.7 Isoelectric focusing-polyacrylamide gel electrophoresis (IEF) 
Ampholyte (40%, pH 3.5-10.0) was used to prepare IEF gel with acrylamide concentration of 5%. 
The isoelectric focusing-polyacrylamide gel electrophoresis (IEF-PAGE) was carried out on BIO-RAD 
power PAC-300 and Mini-PROTEAN 3 cell provided by BIO-RADKWS at 150 V for 75 volt-hours 
(vh), then at 200 V for 500 vh. The IEF-PAGE gel unloaded samples was washed by double distilled 
water, and sliced into pieces of 0.5 cm in length from acidic terminal to basic terminal, then separately 
dipped into Eppendorf tubes containing 2.0 mL of 10 mM KCl for 30 min. The pH value of the liquid 
around each slice was measured. The gel-loaded samples was fixed with 10% trichloroacetic acid for 
30 min, and rinsed thoroughly with destaining solution (0.25% SDS, 33% ethanol, and 10% acetic 
acid). Data were derived from calibration curve of isoelectric point with the length of gel as abscissa 
and pH value as ordinate. 
2.8 Reversed-phase high performance liquid chromatography (HPLC) 
HPLC analyses were performed on an Agilent series 1100 HPLC system fitted with a 
reversed-phase high performance liquid chromatography (RP-HPLC) cartridge, 4.6 mm × 150 mm 
filled with ZORBAX® 300SB-C8, 5 µm (Agilent). The solvent system was the following: solvent A: Mar. Drugs 2008, 6  422
 
 
0.1% (v/v) trifluoroacetic acid (TFA) in H2O; solvent B: 0.1% (v/v) TFA in H2O: acetonitrile 1: 4 (v/v) 
[23-28]. Gradient elution from 50% to 70% of solvent B in 35 min; flow rate: 1 mL/min; detection 
wavelength: 280 nm; column temperature 30 °C. 
2.9 Analysis of saccharides 
The concentrations of methyl glycoproteins and glycoproteins were accurately determined by using 
calibration curves composed of the appropriate monosaccharide(s) obtained with a modified version of 
the colorimetric phenol-sulfuric acid method [29-31]. 200 µg/mL glucose solution was served as 
standard. The absorbance at 490 nm was used to determine the amount of carbohydrate in the sample.   
2.10 Analysis of amino acid components   
The content of amino acids was analyzed by an amino acid automatic analyzer (Hitachi 835-50) 
fitted with ion exchange resin (Hitachi 2619). Appropriate amount of purified and freeze-dried samples 
were weighed and applied into hydrolysis tube. 6 mol/L HCl was added and the vessel was sealed and 
evacuated. Hydrolysis was allowed to proceed at 110°C for 24 h. The samples were then dried, 
dissolved in 0.02 N HCl, and centrifuged at 10,000 rpm for 15 mins. The amino acid compositions 
were then obtained by automatic analysis algorithm of Hitachi L 835-50. The analysis conditions were 
as follows: flow rate: 0.225 mL/min, column temperature: 53°C, column pressure: 80-130 kg/cm
2, 
analysis time: 74 min. 
3. Results and Discussion 
3.1 In vitro bioactivity-guided fractionation 
Cytotoxicity is one of the chemotherapeutic hallmarks of anti-tumor activity [32]. MTT assay, a 
well-established  in vitro model for cytotoxicity against cancer cell lines, was used as one of 
conventional methods for the screening of compounds with potential anti-tumor properties [33]. Since 
it is well known that different cell lines can exhibit different sensitivities to a cytotoxic compound, 
seven tumor cell lines with different origins, morphologies, and tumorigenicities were employed. 
To screen natural products with in vitro anti-tumor activity, the total proteins extract of A. 
subcrenata was subjected to cytotoxicity assay. The results showed that the total proteins extract of A. 
subcrenata suppressed the proliferation of Hela, HL-60, CNE and A549 cells, with IC50 values of 35.6 
µg/mL, 106.0 µg/mL, 145.9 µg/mL and 306.1 µg/mL, respectively (Table 1).   
In order to identify cytotoxic components, the total proteins extract of A. subcrenata was 
fractionated by salting-out at increasing saturation levels of ammonium sulfate. The Fraction-I, 
Fraction-II, and Fraction-III were obtained at the ammonium sulfate saturation of 0-35%, 35-70% and 
70-100%, and their percentage yield was 7.1%, 41.4% and 25.4%, respectively. In the evaluation of 
cytotoxicity of three fractions, the fraction-III exhibited the significant inhibition on the proliferation 
of Hela, HL-60 and KB cells with IC50 values of 6.7 µg/mL, 14.7 µg/mL and 76.5 µg/mL, respectively 
(Table 1). The results suggested that the fraction-III warranted further purification in order to unveil 
the active components of A. subcrenata. Mar. Drugs 2008, 6  423
 
 
Table 1. Cytotoxicity of protein samples against seven human tumor cell lines (IC50 
µg/mL ± SD, n = 3). 
Samples 
Cell lines 
A549 Hela  PC-3  HL-60  KB  BEL-7404  CNE 
Total 
protein 
extract 
306.1±28.4 35.6±2.9  >500  106.0±14.6   >500  >500  145.9±25.9
Fraction-I >500  >500  >500  >500  >500  >500  >500 
Fraction-II >500  >500  >500 >500  >500  >500  >500 
Fraction-III 351.7±40.6 6.7±0.8  >500  14.7±1.7  76.5±4.9 >500  >500 
G-6 >500  >500  >500  123.2±11.3 >500  >500  >500 
G-4 >500  38.2±2.7  >500  67.8±7.1  78.1±9.0  >500  >500 
G-4-2 >500  22.9±2.4  >500  46.1±3.5  57.7±7.2  >500 >500 
Fraction-I : (0-35% saturated (NH4)2SO4); Fraction-II: (35-70% saturated (NH4)2SO4) ; Fraction-III: 
(70-100% saturated (NH4)2SO4) 
3.2 Purification of cytotoxic proteins from A. subcrenata 
Fraction-III was subjected to ion exchange chromatography for purification. Seven A280 nm peak 
fractions were obtained through elution with increasing concentrations of NaCl containing Tris-HCl 
(10 mM, pH 7.46) on DEAE Sepharose Fast Flow column (Figure 1).   
The results of cytotoxicity experiments showed that fraction G-6 had the ability to only suppress the 
proliferation of HL-60 cells (IC50 = 123.2 µg/mL), whereas fraction G-4 appeared to possess inhibitory 
activity not only against HL-60 cells (IC50 = 67.8 µg/mL), but also against Hela cells (IC50 = 38.2 
µg/ml) and KB cells (IC50 = 78.1 µg/mL).   
Furthermore, fraction G-4 was rechromatographed on a Sephadex G-50 column (Figure 2). The 
other subfractions were not found to be active against these seven human tumor cell lines. 
Three A280 nm peak fractions were collected and evaluated for their cytotoxic activities. Among the 
fractions, the IC50 values of fraction G-4-2 towards Hela, HL-60 and KB cell lines were measured to 
be 22.9 µg/mL, 46.1 µg/ml, and 57.7 µg/mL, respectively.   
Fraction-III showed cytotoxic activity against A549, but none of its subfractions presented that 
activity. There are probably synergistic and additive effects among subfractions in the fractionation of 
natural marine medicines. These effects weaken as further isolation and purification proceeds. This is 
corroborated by the observation that each subfraction of fraction-III exhibits lower activity towards 
A549 than fraction-III. In the same way fraction-III presented a lower IC50 than some of its 
subfractions (i.e. against Hela and HL-60 lines), and purified subfractions showed lower activities 
against Hela and HL-60 lines. Mar. Drugs 2008, 6  424
 
 
Figure 1. The curve of elution in DEAE Sepharose Fast Flow chromatography. 
Column specification: 1.6 × 30 cm; Equilibrate liquid: buffer C (Tris-HCl, pH 7.46, 10 
mM); Sample: Fraction-III; Detection wavelength: UV 280 nm; Flow rate: 1.2 mL/min; 
Collection rate: 5 mL/tube. 
 
 
Figure 2. The curve of G-4 separated by Sephadex G-50 chromatography. Column 
specification: 1.0 × 100 cm; Equilibrate liquid: buffer C (Tris-HCl, pH 7.46, 10 mM); 
Sample: G-4; Detection wavelength: UV 280 nm; Flow rate: 0.65 mL/min; Collection 
rate: 3 mL/tube. 
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3.3 Characterization of purified proteins 
To estimate the molecular weight of G-6, Tricine-glycerol SDS-PAGE was employed with 
molecular weight marker ranging from 3.3 kDa to 20.1 kDa as standard. Similarly, SDS-PAGE was 
utilized to estimate the molecular weight of G-4-2, with molecular weight marker ranging from 14.4 
kDa to 97.4 kDa as standard (Figure 3).   
 
Figure 3. The SDS-PAGE of G-6 and G-4-2. (A) Tricine-glycerol SDS-PAGE of G-6. 
lane a: molecular weight marker (range from 3.3 kDa to 20.1 kDa)；lane b: G-6. (B) 
SDS-PAGE of G-4-2. lane a: G-4-2；lane b: molecular weight marker (range from 14.4 
kDa to 97.4 kDa) 
 
 
 
 
 
 
 
 
 
 
 
(A) (B) 
According to calibration curves, the molecular weights of G-6 and G-4-2 were 8.2 kDa and 16.0 
kDa. And the isoelectric points (pI) of G-6 and G-4-2 were 6.6 and 6.1, respectively. The two proteins 
were both single bands in SDS-PAGE and IEF-PAGE. Furthermore, the results of RP-HPLC (Figure 4 
and Figure 5) indicated the purity of G-6 and G-4-2 was 97.6% and 96.8%, respectively. 
 
Figure 4. RP-HPLC of G-6. 
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Figure 5. RP-HPLC of G-4-2. 
 
 
According to modified version of the colorimetric phenol-sulfuric acid method, G-6 may be a 
glycoprotein but not G-4-2. The amino acid compositions of G-6 and G-4-2 were shown in Table 2 and 
Table 3. 
Table 2. The amino acid compositions of G-6. 
Amino 
acid 
The content of amino acid 
(mg/ml) 
The mass percentage of 
amino acid (%) 
Asp 0.0352  11.72 
Thr 0.0160  5.33 
Ser 0.0000  0.00 
Glu 0.0426  14.18 
Gly 0.0102  3.39 
Ala 0.0178  5.93 
Cys 0.0483  16.08 
Val 0.0123  4.09 
Met 0.0056  1.86 
Ile 0.0079  2.63 
Leu 0.0142  4.73 
Tyr 0.0157  5.23 
Phe 0.0039  1.30 
Lys 0.0251  8.36 
His 0.0214  7.12 
Arg 0.0197  6.56 
Pro 0.0000  0.00 
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Table 3. The amino acid compositions of G-4-2. 
Amino 
acid 
The content of amino acid 
(mg/ml) 
The mass percentage of 
amino acid (%) 
Asp 0.2563  15.64 
Thr 0.1005  6.13 
Ser 0.0633  3.86 
Glu 0.2364  14.43 
Gly 0.0741  4.52 
Ala 0.0747  4.56 
Cys 0.0440  2.69 
Val 0.0657  4.01 
Met 0.0613  3.74 
Ile 0.1035  6.32 
Leu 0.0412  2.51 
Tyr 0.0758  4.63 
Phe 0.1056  6.45 
Lys 0.2100  12.82 
His 0.0335  2.04 
Arg 0.0426  2.60 
Pro 0.0000  0.00 
4. Conclusions 
Based upon the results of the in vitro cytotoxicity assay, two proteins from A. subcrenata underwent 
the bioactivity-guided fractionation and purification. Important characteristics of proteins G-6 and 
G-4-2 were identified, showing their molecular weights to be 8.2 kDa and 16.0 kDa and their 
isoelectric points to be 6.6 and 6.1, respectively. G-6, but not G-4-2, is shown to be a glycopeptide.   
Additionally, our present study reveals for the first time the in vitro anti-tumor activity of A. 
subcrenata, and the significance of this finding is deepened by the knowledge that in the past, many 
pharmaceutical agents were discovered by screening natural products from plants, animals, marine 
organisms and microorganisms [34]. A. subcrenata is a member of mollusks constituting a large 
marine animal family. Some mollusks such as oyster have been found to contain compounds with 
anti-tumor activities. The extract of oyster has significant in vitro cytotoxic effect on human A549 cell 
lines [35], and in vivo anti-tumor activity against murine hepatic cancer [36]. In addition, there has 
been much interest in the research on bioactive peptides from marine sources. For example, protein 
from Chlamys farreri (PCF), a species of Chinese scallop, was recently shown to have potential 
antioxidant activity and protective effect against ultraviolet (UV) irradiation [37]. Similarly, a group in 
Korea reported that methanolic extracts from seaweed Plocamium telfairiae (PTE) exhibited a 
cytotoxic effect against HT-29 human colon carcinoma cells [38]. 
The combination of chemical and biological approaches provides scientists with a valuable tool to 
efficiently investigate a wide array of natural products. As a whole, the results in our paper suggest that Mar. Drugs 2008, 6  428
 
 
A. subcrenata is a promising resource in the development of novel drugs for its anti-tumor potential. 
Further studies on mechanism of bioactive proteins, their structure-function relationships and the in 
vivo anti-tumor effects of A. subcrenata are currently underway. 
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